Clinical significance and potential application of cuproptosis-related genes in gastric cancer

Table 1 Univariate and multivariate analysis of the correlation of differentially expressed cuproptosis-related gene expression with overall survival among gastric cancer patients

Gene	Total, n	Univariate analysis		Multivariate analysis
		Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
ATP7A	370	1.037 (0.725-1.483)	0.842
ATP7B	370	0.922 (0.781-1.088)	0.334
CDKN2A	370	0.985 (0.887-1.094)	0.782
DLAT	370	0.785 (0.577-1.069)	0.124
DLD	370	0.961 (0.678-1.363)	0.825
FDX1	370	0.737 (0.533-1.018)	0.064	0.735 (0.534-1.011)	0.059
GCSH	370	1.054 (0.769-1.446)	0.744
GLS	370	1.052 (0.845-1.310)	0.650
LIAS	370	0.730 (0.498-1.068)	0.105
LIPT1	370	1.168 (0.713-1.916)	0.537
LIPT2	370	1.014 (0.794-1.294)	0.912
MTF1	370	0.642 (0.410-1.006)	0.053	0.661 (0.411-1.064)	0.088
NFE2L2	370	0.701 (0.477-1.031)	0.071	0.809 (0.534-1.225)	0.317
NLRP3	370	1.279 (0.946-1.729)	0.110
PDHA1	370	0.873 (0.632-1.206)	0.409
PDHB	370	1.051 (0.686-1.611)	0.818
SLC31A1	370	0.834 (0.653-1.065)	0.146

CI: Confidence interval.

Table 2 Univariate and multivariate analysis of the correlation of differentially expressed cuproptosis-related gene expression with disease-specific survival among gastric cancer patients

Gene	Total, n	Univariate analysis		Multivariate analysis
		Hazard ratio (95%CI)	P value	Hazard ratio (95%CI)	P value
ATP7A	349	1.032 (0.656-1.625)	0.891
ATP7B	349	0.957 (0.776-1.180)	0.680
CDKN2A	349	1.019 (0.894-1.162)	0.774
DLAT	349	0.701 (0.471-1.043)	0.080	1.185 (0.708-1.982)	0.518
DLD	349	0.657 (0.415-1.039)	0.072	0.926 (0.529-1.622)	0.788
FDX1	349	0.668 (0.441-1.013)	0.057	0.722 (0.448-1.164)	0.181
GCSH	349	1.280 (0.863-1.900)	0.220
GLS	349	1.041 (0.788-1.376)	0.778
LIAS	349	0.509 (0.310-0.836)	0.008	0.578 (0.338-0.989)	0.045
LIPT1	349	1.117 (0.594-2.101)	0.731
LIPT2	349	1.014 (0.745-1.381)	0.928
MTF1	349	0.581 (0.329-1.023)	0.060	0.604 (0.321-1.135)	0.117
NFE2L2	349	0.584 (0.360-0.947)	0.029	0.709 (0.414-1.215)	0.211
NLRP3	349	1.082 (0.716-1.634)	0.710
PDHA1	349	0.676 (0.441-1.036)	0.072	0.780 (0.469-1.297)	0.338
PDHB	349	0.809 (0.465-1.408)	0.454
SLC31A1	349	0.768 (0.564-1.046)	0.094	1.029 (0.717-1.476)	0.878

CI: Confidence interval.

Table 3 Potential perturbagens of interactive prognostic cuproptosis-related genes

Perturbagen	Moa	Raw_cs	FDR_q_nlog 10
Fluconazole	Sterol demethylase inhibitor	0.79	1.03
KD-025	Rho associated kinase inhibitor	0.77	0.95
Clofarabine	Ribonucleoside reductase inhibitor	0.76	0.89
Tramadol	Opioid receptor agonist, Norepinephrine reuptake inhibitor, Serotonin reuptake inhibitor	0.76	0.89
Doxorubicin	Topoisomerase inhibitor	0.75	0.88
AXD-5438	CDK inhibitor	0.73	0.80
BRD-K67174965	Mucolytic	0.73	0.79
Faropenem	Lactamase inhibitor	0.72	0.76
Clocortolone-pivalate	Steroid	0.72	0.68
Ganglioside	Src activator	0.71	0.46